Thursday, October 22, 2020 10:59:55 AM
First of all: Generics could be “subject” of indirect infringement only … could not be “subject” of direct infringement. (While the United States Patent Act does not directly distinguish "direct" and "indirect" infringement, it has become customary to describe infringement under 35 U.S.C. § 271(a) as direct infringement, while grouping 35 U.S.C. § 271(b) and 35 U.S.C. § 271(c) together as "indirect" ways of infringing a patent.). The patient or physician will infringe the patent directly, the Generics could infringe indirectly only … they are sued for contributory and / or induced infringement only.
Indirect infringement
It could be:
a.) contributory infringement
b.) induced infringement
a.) Contributory infringement
Generic will be liable for contributory infringement due to the launch (sells or offers to sell) IF substantial non-infringing use does not exist.
Substantial non-infringing does not have an exact (measurable) definition, because it does not a question of volume, any reasonable use is a substantial use, even if not commercially viable.
Meanwhile not all of non-infringing use (eg. for dry eye) matters – only the approved / labeled one (in this case MARINE) – I am not aware of any case where an approved / labeled indication was determined as NON-sunstantial.
Just like in case of MARINE patents (use for LESS than 12 weeks was determined as substantial despite it is 5% of the total use only) contributory infringement claim (if any) of R-IT patent will be denied.
b.) Induced infringement
To prove inducement of infringement, showing that a patient or physician will directly infringe the patent is necessary (a prerequisite), however the mere knowledge of possible infringement by others did not amount to inducement, the specific intent and action to induce infringement had to be proven. Direct (label) or circumstantial (e.g. promotional material) evidence could prove it, these are the specific intent and action … the evidence that inevitably lead some physicians to (directly) infringe. The proof that any direct infringer was actually persuaded to infringe by the evidence is not necessary, the existence of the evidence is enough. The quantity of available supply or presentation of past … (or let be generous: future) market – meanwhile (could) show / prove Generics economical intent - DOES NOT lead physicians to infringe the patent … these are not legal evidences of infringement. It is similar to “mere knowledge” … a mere expectation of infringement by others did not amount to inducement.
In other words, the non-infringing use (except a “special” circumstance, see below) is irrelevant for inducement. Induced infringement determined – always – based on evidence[s] (specific intent and action) … had not been based on lack of “substantial non-infringing” ever.
The Generics’ label (MARINE indication only) is not a direct evidence; the label will not lead any physicians to infringe the R-IT patents. Circumstantial evidence might be exist in the future (not likely after TEVA / GSK case) but does not exist now.
All together: I do not see how Amarin could block Generics by any (valid) patents.
- - - - - - -
Will do the Generics a specific intent or action IN THE FUTURE to induce infringement?(No direct evidence exist, the label does not encourage inducement.)
The answer was:NO.
If substantial noninfringing use does not exist it proves contributory infringement but still does not say anything about induced infringement, since the lack of substantial noninfringing use is not a specific intent or action.
“Translate” for Vascepa:
a.) substantial noninfringing use exist (MARINE indication) -> no contributory infringement and - most likely - the court will NOT assume (without any evidence) that Generics will (anytime in the future) actively promote the infringing use.
b.) But let’s say substantial noninfringing use does not exist (but it is just for this post, since it exists …)
(i) it will be the proof of contributory infringement
(ii) it will not prove inducement, induced infringement will not be determined (without any specific intent or action) due to the lack of substantial noninfringing use
It rigorously interpret the evidence and determined that inevitably lead some physicians to (directly) infringe.
Meanwhile it narrow the “playground” (limit the possibilities) of the Generics, it does not forbid skinny-label.
The more likely consequence of the case is that the Generics will test – with extreme scrutiny – every word / context of every material but will not stop them.
- - - - - - -
Best,
G
Disclosure: I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.
Recent AMRN News
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM